DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Surgical Site Infections pipeline, providing valuable insights into emerging therapies and companies.

 

DelveInsight’s, “Surgical Site Infection Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Surgical Site Infection pipeline landscape. It covers the Surgical Site Infection pipeline drug profiles, including Surgical Site Infection clinical trials and nonclinical stage products. It also covers the Surgical Site Infection therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Surgical Site Infections Pipeline treatment landscape of the report, click here @ Surgical Site Infections Pipeline Outlook

 

Key Takeaways from the Surgical Site Infections Pipeline Report

• DelveInsight’s Surgical Site Infections Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Surgical Site Infections.
• The leading Surgical Site Infections Companies include Destiny Pharma PLC, POLYPID, Exoxemis, Covira Surgical Inc., Eupraxia Pharmaceuticals, Sonoran Biosciences, and Others.
• Promising Surgical Site Infections Pipeline Therapies include mupirocin calcium ointment, 3M Skin and Nasal Antiseptic, BACTROBAN® Nasal ong, Intranasal povidone-iodine, 70% v/v Isopropyl Alcohol Surgical Solution, Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic, ZuraPrep with 70% IPA, Ciprodiazole, gentamicin-collagen sponge dipped in saline, ertapenem sodium, D-PLEX, and others
• Surgical site infection typically appear 5 to 7 days post-procedure, however can develop up to 3 weeks after (especially if a prosthesis is inserted). The common clinical features of surgical site infections include: Spreading erythema; localized pain; Pus or discharge from the wound; and Persistent pyrexia.
• The Surgical site infection companies and academics that are working to assess challenges and seek opportunities that could influence Surgical Site Infection R&D. The Surgical site infection therapies under development are focused on novel approaches to treat/improve the disease condition.

 

For further information, refer to the detailed Surgical Site Infections Unmet Needs, Surgical Site Infections Market Drivers, and Surgical Site Infections Market Barriers, click here for Surgical Site Infections Ongoing Clinical Trial Analysis

 

Surgical Site Infections Overview

A surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be superficial infections involving the skin only. Other surgical site infections are more serious and can involve tissues under the skin, organs, or implanted material.

 

Request a sample and discover the recent advances in Surgical Site Infections Ongoing Clinical Trial Analysis and Medications, click here @ Surgical Site Infections Treatment Landscape

 

Surgical Site Infections Emerging Drugs Profile

 

• XF-73: Destiny Pharma plc

XF-73 is a synthetic dicationic porphyrin derivative with antibacterial activity. XF-73 has confirmed bactericidal activity. It is designated by the International Non-proprietary Name (INN) of exeporfinium chloride by the World Healthcare Organisation (WHO). XF-73 has been tested in vitro against a range of clinically important S. aureus isolates. It is active against methicillin-resistant S. aureus (MRSA), methicillin-sensitive S. aureus (MSSA), hospital associated-MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA), daptomycin resistant S. aureus, low- and high-level mupirocin-resistant S. aureus, linezolid-resistant MRSA and vancomycin-intermediate S. aureus (VISA).

 

• D-PLEX100: POLYPID

PLEX (Polymer-Lipid Encapsulation matriX) platform is made of alternating layers of polymers and lipids that entrap a therapeutic drug to form a protected reservoir. PLEX-based drug reservoirs enable prolonged delivery of unmodified drugs over periods ranging from days to several months, a rare combination of attributes. The novel D-PLEX100 product candidate delivers a broad-spectrum antibiotic, doxycycline, generating high local concentration over four weeks with minimal systemic exposure

 

Dive deep into rich insights for drugs for Surgical Site Infections Market Drivers and Surgical Site Infections Market Barriers, click here @ Surgical Site Infections Unmet Needs and Analyst Views

 

Surgical Site Infections Pipeline Therapeutics Assessment

There are approx. 5+ Surgical Site Infections companies which are developing the Surgical Site Infections therapies. The Surgical Site Infections companies which have their Surgical Site Infection drug candidates in the most advanced stage, i.e. phase III include, POLYPID.

 

Scope of the Surgical Site Infections Pipeline Report

• Coverage- Global
• Surgical Site Infections Companies- Destiny Pharma PLC, POLYPID, Exoxemis, Covira Surgical Inc., Eupraxia Pharmaceuticals, Sonoran Biosciences, and Others.
• Surgical Site Infections Pipeline Therapies – mupirocin calcium ointment, 3M Skin and Nasal Antiseptic, BACTROBAN® Nasal ong, Intranasal povidone-iodine, 70% v/v Isopropyl Alcohol Surgical Solution, Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic, ZuraPrep with 70% IPA, Ciprodiazole, gentamicin-collagen sponge dipped in saline, ertapenem sodium, D-PLEX, and others
• Surgical Site Infections Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Surgical Site Infections Mergers and acquisitions, Surgical Site Infections Licensing Activities @ Surgical Site Infections Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Surgical Site Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Surgical Site Infection – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. D-PLEX100: POLYPID
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. XF-73: Destiny Pharma plc
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. F573: Beijing Continent Pharmaceutical
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EP-201: Eupraxia Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Surgical Site Infection Key Companies
21. Surgical Site Infection Key Products
22. Surgical Site Infection- Unmet Needs
23. Surgical Site Infection- Market Drivers and Barriers
24. Surgical Site Infection- Future Perspectives and Conclusion
25. Surgical Site Infection Analyst Views
26. Surgical Site Infection Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services